Abstract: Disclosed embodiments relate to systems and methods for providing medical data to predict patient events. Techniques include accessing, from one or more data sources, patient data associated with a patient; extracting, from the patient data, a sequence of events associated with the patient; inputting the sequence of events associated with the patient into a trained machine learning model; receiving, as an output of the trained machine learning model, a sequence of predicted events associated with the patient, the sequence of predicted events including at least one event that is predicted to occur; and transmitting an indication of the at least one predicted event.

Abstract: The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.

Abstract: The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.

Abstract: A rechargeable magnesium oxygen battery including a negative electrode, a positive electrode, a non-aqueous magnesium ion electrolyte layer between the negative and positive electrodes, and an oxygen restrictor. The oxygen restrictor is configured to restrict oxygen crossover from the positive electrode to the negative electrode.

Abstract: The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.

Abstract: A non-aqueous type magnesium oxygen battery including a negative electrode, a positive electrode, a non-aqueous magnesium ion conductor, and a promoter is described. The negative electrode is configured to absorb magnesium and release magnesium ion. The positive electrode is configured to produce a discharge product that includes magnesium and oxygen during a discharge process of the battery. The non-aqueous magnesium on conductor is between the negative electrode and the positive electrode. The promoter is included with the positive electrode. The promoter is configured to promote MgO2 (magnesium peroxide) production during the discharge process of the battery.

Abstract: The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.

Abstract: A non-aqueous type magnesium oxygen battery including a negative electrode, a positive electrode, a non-aqueous magnesium ion conductor, and a promoter is described. The negative electrode is configured to absorb magnesium and release magnesium ion. The positive electrode is configured to produce a discharge product that includes magnesium and oxygen during a discharge process of the battery. The non-aqueous magnesium on conductor is between the negative electrode and the positive electrode. The promoter is included with the positive electrode. The promoter is configured to promote MgO2 (magnesium peroxide) production during the discharge process of the battery.

Abstract: A rechargeable magnesium oxygen battery including a negative electrode, a positive electrode, a non-aqueous magnesium ion electrolyte layer between the negative and positive electrodes, and an oxygen restrictor. The oxygen restrictor is configured to restrict oxygen crossover from the positive electrode to the negative electrode.

Abstract: The present invention relates to novel methods for detecting a member of a known binding pair in a sample, including a cell, where one member of the pair (termed the “receptor”) is expressed by a bacteriophage, which phage is then used to detect the presence of the other member of the pair (termed the “ligand” or “target”). Rather than detecting the binding of the phage using antibody-based technology, the present invention relates to detecting marker molecule associated with the phage. In one aspect, the invention relates to identifying an antigen-bearing moiety (e.g., a red blood cell antigen) of interest present on a cell, e.g., a red blood cell, using antibody-displaying bacteriophage, as well as detecting anti-red blood cell auto- or alloantibodies and/or complement in a sample, using antiglobulin reagent-displaying bacteriophage and detecting a marker molecule associated with the phage. In one aspect, the phenotype of the phage is not linked with the genotype of the phage.

Abstract: The invention relates to Anti-TEM 1 anti-bodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.

Abstract: A rechargeable magnesium oxygen battery, which can be recharged with high efficiency, including a negative electrode, a positive electrode, and an electrolyte catalyst. The negative electrode is configured to release magnesium ions during discharge of the battery, and configured to precipitate elemental magnesium during charging of the battery. The positive electrode is configured to precipitate discharge products that include at least magnesium and oxygen during discharge of the battery, and for releasing magnesium ions during charging of the battery. The electrolyte catalyst is between the negative electrode and the positive electrode. The electrolyte catalyst can be any suitable compound configured to facilitate adsorption of at least one of the electrolyte catalyst and anions thereof on the discharge product.

Abstract: The invention relates to Anti-TEM 1 anti-bodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.

Abstract: The present invention relates to novel methods for detecting a member of a known binding pair in a sample, including a cell, where one member of the pair (termed the “receptor”) is expressed by a bacteriophage, which phage is then used to detect the presence of the other member of the pair (termed the “ligand” or “target”). Rather than detecting the binding of the phage using antibody-based technology, the present invention relates to detecting marker molecule associated with the phage. In one aspect, the invention relates to identifying an antigen-bearing moiety (e.g., a red blood cell antigen) of interest present on a cell, e.g., a red blood cell, using antibody-displaying bacteriophage, as well as detecting anti-red blood cell auto- or alloantibodies and/or complement in a sample, using antiglobulin reagent-displaying bacteriophage and detecting a marker molecule associated with the phage. In one aspect, the phenotype of the phage is not linked with the genotype of the phage.

Abstract: The present invention is directed to methods which exploit the discovery of tomoregulin-2 (TR2) in amyloid plaques in Alzheimer's disease using TR2-sepcific antibodies; methods and compositions comprising TR2-specific antibodies for the diagnosis and treatment of Alzheimer's disease; methods and compositions comprising immunizing TR2 peptides to induce an immune response, thereby reducing/inhibiting plaque formation; and methods and compositions comprising enzyme inhibitors to blocking the enzymatic release of TR2 ectodomain from the cell surface or inhibit TR2 protein translation by RNA interference technology.

Abstract: The invention includes Rh(D) binding proteins, including antibodies, and DNA encoding such proteins. Methods of generating such proteins and DNAs are also included.

Abstract: The invention includes Rh(D) binding proteins, including antibodies, and DNA encoding such proteins. Methods of generating such proteins and DNAs are also included.

Abstract: The invention includes Rh(D) binding proteins, including antibodies, and DNA encoding such proteins. Methods of generating such proteins and DNAs are also included.

Abstract: The present invention relates to novel methods of identifying and producing an anti-platelet autoantibody. More preferably, the invention relates to identification and production of a human monoclonal anti-platelet autoantibody. Additionally, the invention relates to methods for producing and identifying inhibitors of an anti-platelet autoantibody binding with a platelet, or a platelet component. Moreover, the invention relates to methods for treating or alleviating a disease, disorder or condition mediated by an anti-platelet autoantibody specifically binding with a platelet, or a component thereof, such as, but not limited to, idiopathic thrombocytopenic purpura, among others.

Abstract: The present invention relates to novel methods for detecting a member of a known binding pair in a sample, including a cell, where one member of the pair (termed the “receptor”) is expressed by a bacteriophage, which phage is then used to detect the presence of the other member of the pair (termed the “ligand” or “target”). Rather than detecting the binding of the phage using antibody-based technology, the present invention relates to detecting the nucleic acid associated with the phage. In one aspect, the invention relates to identifying an antigen-bearing moiety (e.g., a red blood cell antigen) of interest present on a cell, e.g., a red blood cell, using antibody-displaying bacteriophage, as well as detecting anti-red blood cell auto- or alloantibodies and/or complement in a sample, using antiglobulin reagent-displaying bacteriophage and detecting a nucleic acid associated with the phage.